| Wong, David |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection |
|
|
| Recruiting | N/A | 5000 | Canada, US | All approved therapies for the treatment of Chronic Hepatitis B (CHB) | Target PharmaSolutions, Inc. | Hepatitis B, Hepatitis, Liver Diseases | 01/26 | 01/26 | | |
| Smith, Wendy B |
CREST-H, NCT03121209: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics |
|
|
| Active, not recruiting | 3 | 385 | Canada, US | Revascularization, Intensive Medical Management (IMM) alone | Columbia University, National Institute of Neurological Disorders and Stroke (NINDS), Mayo Clinic, University of Alabama at Birmingham, University of Maryland, University of California, Los Angeles | Internal Carotid Artery Stenosis, Cognitive Impairment | 01/27 | 07/27 | | |
RESCUE, NCT04693715: Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy |
|
|
| Completed | 2 | 82 | US | RNS60, Placebo | Revalesio Corporation | Stroke, Ischemic | 11/23 | 11/23 | | |
NCT05232838: US Pilot Study of the CereVasc® EShunt® System in Normal Pressure Hydrocephalus |
|
|
| Recruiting | N/A | 50 | US | eShunt Implant | CereVasc Inc, AlvaMed, Inc., Simplified Clinical Data Systems, LLC | Hydrocephalus, Normal Pressure, Hydrocephalus | 01/25 | 01/30 | | |
| Recruiting | N/A | 24000 | US | Text4Baby or Bright by Text Referral, Nurture Program Warm Referral, Video Interaction Project, Family Check-UP, Smart Beginnings, Healthy Families America Warm Referral, Family Center Warm Referral | University of Pittsburgh, The Grable Foundation, The Shear Family Foundation, Heinz Endowments | Child Development, Child Language, Child Behavior Problem, Parenting, Parent Child Abuse | 12/30 | 12/31 | | |
DOORwaY90, NCT04736121: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients |
|
|
| Active, not recruiting | N/A | 100 | US | Resin microspheres containing yttrium-90 (Y-90) | Sirtex Medical, Bright Research Partners | Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | 10/25 | 12/26 | | |
| Schiff, Eugene |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein |
|
|
| Recruiting | 3 | 160 | Europe, Canada, US, RoW | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride | Takeda, Takeda Development Center Americas, Inc. | Alpha1-Antitrypsin Deficiency | 03/27 | 03/29 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection |
|
|
| Recruiting | N/A | 5000 | Canada, US | All approved therapies for the treatment of Chronic Hepatitis B (CHB) | Target PharmaSolutions, Inc. | Hepatitis B, Hepatitis, Liver Diseases | 01/26 | 01/26 | | |
| Sarkar, Souvik |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Terminated | 2b | 98 | Europe, Canada, US, RoW | EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo | Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc. | Non-Alcoholic Steatohepatitis | 10/21 | 11/21 | | |
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH |
|
|
| Completed | 2 | 99 | US | CS0159 (Linafexor), placebo | Cascade Pharmaceuticals, Inc, Laboratory Corporation of America | Nonalcoholic Steatohepatitis (NASH) | 11/23 | 11/23 | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 06/24 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis |
|
|
| Active, not recruiting | 1/2 | 42 | US | CNP-104, Placebo | COUR Pharmaceutical Development Company, Inc. | Primary Biliary Cholangitis | 01/26 | 01/26 | | |
EXPLORER, NCT04165343: Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on |
|
|
| Completed | N/A | 81 | US | Positron Emission Tomography (PET) on EXPLORER, PET Scan, Magnetic Resonance Imaging, MRI, Echocardiogram and Electrocardiogram, Echo and EKG or ECG, Blood test, Lab test | University of California, Davis | Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) | 05/23 | 05/23 | | |
| Active, not recruiting | N/A | 44467 | US | | Guardant Health, Inc., Premier Research Group plc | Colorectal Cancer | 03/24 | 12/25 | | |
| Dhaliwal, Sandeep |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
| Recruiting | 2 | 42 | US | Sulfasalazine, Azulfidine, Placebo | Brigham and Women's Hospital | Primary Sclerosing Cholangitis | 09/24 | 11/24 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Active, not recruiting | 1/2 | 4 | Europe, US | VTX-801 | Vivet Therapeutics SAS | Wilson's Disease | 12/24 | 06/29 | | |
EXPLORER, NCT04165343: Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on |
|
|
| Completed | N/A | 81 | US | Positron Emission Tomography (PET) on EXPLORER, PET Scan, Magnetic Resonance Imaging, MRI, Echocardiogram and Electrocardiogram, Echo and EKG or ECG, Blood test, Lab test | University of California, Davis | Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) | 05/23 | 05/23 | | |
NCT03560037: Use of a Distal Colonoscope Attachment to Increase Detection of Sessile Serrated Adenomas |
|
|
| Completed | N/A | 427 | US | Endocuff Vision Assisted Colonoscopy | University of California, Davis | Sessile Serrated Adenoma | 12/23 | 12/23 | | |
NCT02754037: Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study |
|
|
| Active, not recruiting | N/A | 120 | US | Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), Magnetic resonance proton density fat fraction (MR-PDFF), Magnetic resonance elastography (MRE), PET Explorer | University of California, Davis, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) | 06/25 | 06/25 | | |
| Recruiting | N/A | 10000 | Europe, US | | Target PharmaSolutions, Inc. | Hepatocellular Cancer | 10/25 | 10/25 | | |
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease |
|
|
| Recruiting | N/A | 15000 | US | | Target PharmaSolutions, Inc. | Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis | 10/25 | 10/25 | | |
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection |
|
|
| Recruiting | N/A | 5000 | Canada, US | All approved therapies for the treatment of Chronic Hepatitis B (CHB) | Target PharmaSolutions, Inc. | Hepatitis B, Hepatitis, Liver Diseases | 01/26 | 01/26 | | |
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | N/A | 15000 | Europe, US | | Target PharmaSolutions, Inc. | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 07/36 | 07/36 | | |
| Chak, Erik |
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection |
|
|
| Recruiting | N/A | 5000 | Canada, US | All approved therapies for the treatment of Chronic Hepatitis B (CHB) | Target PharmaSolutions, Inc. | Hepatitis B, Hepatitis, Liver Diseases | 01/26 | 01/26 | | |
| Piquant, Dominique |
| Recruiting | N/A | 1000 | US | | University of Texas Southwestern Medical Center, University of California, San Francisco, Scripps Health, University of Wisconsin, Madison, University of Florida, University of Arizona, Stanford University, Columbia University, Weill Medical College of Cornell University, Baylor Scott and White Health, Mayo Clinic, University of Chicago, Digestive Health Foundation, W.L.Gore & Associates, University of Minnesota, Northwestern University | Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS) | 07/25 | 12/27 | | |
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection |
|
|
| Recruiting | N/A | 5000 | Canada, US | All approved therapies for the treatment of Chronic Hepatitis B (CHB) | Target PharmaSolutions, Inc. | Hepatitis B, Hepatitis, Liver Diseases | 01/26 | 01/26 | | |
